期刊文献+

精氨酸酶1在肝细胞癌中的表达及其临床病理意义 被引量:1

The expression of arginase I in heptocellular carcinoma and its clinicopathological significance
原文传递
导出
摘要 目的检测人类精氨酸酶1(ARG1)在肝细胞癌(HCC)中的表达,分析其与患者临床病理特征的关系。方法利用高通量组织芯片技术和免疫组织化学方法评价167例HCC及癌旁肝组织中ARG1蛋白的表达情况,采用x2检验和Spearman秩相关分析ARGl蛋白表达与各临床病理特征间的关系。应用实时荧光定量PCR方法检测68例HCC及其癌旁肝组织中的ARG1 mRNA表达水平。结果HCC中ARGl蛋白表达水平为3.540±3.702,明显低于癌旁肝组织(10.290±2.303;t=-22.421,P=0.000)。ARG1表达与HCC分化程度、组织学分级、微血管侵犯、术前甲胎蛋白水平、术后复发有关(P值均〈0.05)。68例HCC组织中ARG1 mRNA表达水平为0.0997(O.213),低于癌旁肝组织[O.563(O.459);u=-6.544,P=0.000]。结论ARGl在HCC中低表达,其可能参与HCC发生发展。检测ARG1表达可能有助于HCC辅助诊断、评估分化程度及预后判断。 Objective To investigate the expression of arginase I (ARG1) in hepatocellular carcinoma (HCC) and to analyze its correlation with clinicopathological features. Methods The expression of ARG1 at protein level in 167 samples of HCC and corresponding adjacent liver tissue was detected with high-throughput tissue microarray technique and immunohistochemistry. The correlation between ARG1 expression and clinicopathological features was analyzed with X2 test and Spearman rank correlation analysis. The expression of ARG1 at mRNA level in 68 samples of HCC and corresponding adjacent liver tissue was determined by real-time polymerase chain reaction (real-time PCR). Results The expression of ARG1 at protein level in HCC (3. 540 ± 3. 702) was significantly lower than that of the corresponding adjacent liver tissues (10. 290 ± 2. 303)(t =- 22. 421, P = 0. 000). The ARG1 expression was correlated with differentiation degree of HCC, histological grade, vascular invasion, preoperative level of α-fetoprotein (AFP) and recurrence after operation (all P〈 0.05). The ARG1 expression at mRNA level in 68 HCC tissue [0. 0997(0. 213)-] was lower than that of the corresponding adjacent liver tissues [0. 563 (0. 459)], and the difference was statistical significant (u= -6. 544,P=0. 000). Conclusion Low expression of ARG1 in HCC may take part in HCC genesis and development. Detecting the expression of ARG1 may be helpful in HCC diagnosis,differentiation degree and prognosis assessment.
出处 《中华消化杂志》 CAS CSCD 北大核心 2012年第2期113-117,共5页 Chinese Journal of Digestion
基金 卫生部科学研究基金-福建省卫生教育联合攻关计划项目(WKJ2008-2-63)
关键词 肝细胞 精氨酸酶 聚合酶链反应 芯片分析技术 免疫组织化学 预后 Carcinoma, Hepatocellular Arginase Polymerase chain reaction Microchip analytical procedures Immunohistochemistry Prognosis
  • 相关文献

参考文献5

二级参考文献19

  • 1祝峙,朱明华.乙型肝炎病毒X基因与肝细胞癌[J].中华病理学杂志,2006,35(7):423-426. 被引量:1
  • 2Kononen J,Bubendorf L,Kallioniemi A,et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens.Natmed,1998,4 (7):844-847 被引量:1
  • 3Camp RL,Charette LA,Rimm DL.Validation of tissue microarray technology in breast carcinoma.Lab Invest,2000,80:1943-1949 被引量:1
  • 4Rubin MA,Dunn R,Strawderman M,et al.Tissue microarray sampling strategy for prostate cancer biomarker analysis.Am J Surg Pathol,2002,26:312-319 被引量:1
  • 5Farazi PA, DePinho RA. Hepatocenular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 2006, 6 ( 9 ) : 674- 687. 被引量:1
  • 6El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132(7) :2557-2576. 被引量:1
  • 7Marchio A, Terris B, Meddeb M, et al. Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridization. Mol Pathol, 2001,54 (4) :270-274. 被引量:1
  • 8Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl, 2004,10(2 Suppl 1 ) : S3-S8. 被引量:1
  • 9Park YN, Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol, 2006,45(5) :734-743. 被引量:1
  • 10Kojiro M, Reskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis, 2005,25(2) :133-142. 被引量:1

共引文献284

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部